Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week, although it may not quite seem that way, if only because you most likely have not moved very much since waking this morning. Nonetheless, we hope the weekend respite provided some sort of respite from the deluge of headlines and anxieties afflicting our world. In any event, the time has come to assume what resembles the usual routine of online meetings and deadlines. So grab a cup of stimulation and get started. On that note, here are a few tidbits to help you along. Stay safe and stay in touch.

A recent $2 trillion relief package that lawmakers passed on Friday could mean drug pricing advocates might be waiting a long while for legislation, possibly until November, weeks after Election Day, STAT reports. Until now, late May was widely viewed as a final 2020 deadline for lawmakers to take action on key health policy issues, including legislation to lower the price of prescription drugs. “I think Nov. 30 is the new May 22,” says Ben Wakana, the executive director of the advocacy group Patients for Affordable Drugs Now.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.